NIH begins early human clinical trial of VSV Ebola vaccine
Researchers at NIAID are conducting the early phase trial to evaluate the vaccine, called VSV-ZEBOV, for safety and its ability to generate an immune system response in healthy adults who are given two intramuscular doses, called a prime-boost strategy. October 22, 2014